H.U. Group Holdings, the Tokyo-listed diagnostics company whose units include Fujirebio, reported group sales of ¥62.59bn for the quarter to June 2026, up 1.9% from a year earlier. Operating profit jumped 141% to ¥2.1bn, and net profit attributable to shareholders reached ¥1.57bn, reversing a ¥1.20bn loss in the same quarter last year.
The turnaround centered on testing and related services, the group's largest segment, which swung from an operating loss of ¥800mn to a profit of ¥674mn. Segment revenue rose only 0.8%, to ¥39.6bn, helped by growth in genomic testing. The profit recovery came from price adjustments that widened margins and from fixed-cost cuts, not from a jump in sales volume.
The clinical-diagnostics reagent business grew faster: revenue rose 16.2% to ¥16.4bn on overseas neuro-related sales, contract manufacturing work and a weaker yen, while operating profit there rose 5.6% to ¥2.44bn. In May 2026 the company won certification in Europe for a blood-based in-vitro diagnostic reagent that measures pTau217, a biomarker used to check for pathological changes linked to Alzheimer's disease, part of its "H.U.2030 2.0" growth strategy for neuro-diagnostics.
The healthcare-related services segment moved the other way. Revenue fell 17.4% to ¥6.6bn and operating profit fell 30.8% to ¥520mn, after the company sold its stake in a domestic subsidiary in December 2025 and absorbed higher personnel costs in its sterilization and surgical-support business.
Management kept its full-year outlook unchanged: sales of ¥256bn (up 3.5%) and operating profit of ¥9.0bn (up 88.3%) for the year to March 2027, even as its net-profit forecast is guided down 26.7% to ¥5.0bn. The company also bought back 489,400 shares for ¥1.58bn during the quarter and removed European subsidiary ADx NeuroSciences from its consolidated accounts after merging it into Fujirebio Europe on April 1, 2026.